Important safety information
Longevity
Certain longevity therapies, including NAD+, Semorelin, and peptide formulations, are compounded medications that have not been evaluated by the FDA for safety, efficacy, or quality. Compounded products may differ in dose, formulation, sterility, or purity compared to FDA-approved versions.
Potential risks may include: inaccurate dosing, contamination, injection site reactions, hormonal fluctuations, allergic responses, and other unforeseen effects. The FDA has issued warnings about compounded peptides and other compounded therapies being associated with dosing errors and adverse events.
Results will vary depending on each patient’s health status, age, baseline biomarkers, and adherence to the Framework program. Some patients experience improvements in energy, sleep, body composition, or cognition, but outcomes are highly individualized and not guaranteed.
Framework longevity programs may include lifestyle and nutritional recommendations in combination with medical therapies. Reported benefits reflect the combined effect of lifestyle changes, supplementation, and provider-guided treatment — not medication alone.
All prescriptions are provided only when deemed medically appropriate and may not be suitable for all individuals. Some therapies are used “off-label” for longevity purposes, meaning they are not FDA-approved for this indication.
Always consult with a licensed healthcare professional before starting any longevity treatment or compounded product.
Weight Loss
**Important Safety Information (Compounded Product – Not FDA-Approved)**
This medication is compounded and has not been evaluated by the FDA for safety, efficacy, or quality. Compounded GLP-1 products may differ in dose, formulation, sterility, or purity from FDA-approved versions. Risks may include: inaccurate dosing, contamination, allergic reactions, gastrointestinal effects (nausea, vomiting), hypoglycemia, dehydration, and undetermined risks (e.g., thyroid safety not established). The FDA has issued warnings about compounded semaglutide products being associated with overdoses and serious adverse events, including dosing errors and patient harm. Talk with your doctor to fully understand the risks and whether a compounded product is appropriate for your situation.
Results will vary depending on each patient’s starting weight, health profile, and adherence to the Framework program. Initial changes in body composition may include reductions in waist, hips, thighs, arms, and chest measurements, but individual outcomes are not typical.
Patients in the Framework program follow a reduced-calorie diet and regular physical activity as directed by their care team. Reported fat and weight loss reflect lifestyle changes in combination with medical guidance and are not guaranteed.
Medication prescriptions are provided only when deemed medically appropriate and may not be suitable for all individuals. Framework patients who are prescribed weight-management medications typically see an average of 1–2 pounds of weight loss per week after the first month, as part of a structured program that combines nutrition, exercise, and behavior support.
Always consult with a licensed healthcare professional before starting any medication or weight-loss program.